Mauro Keiserman
Overview
Explore the profile of Mauro Keiserman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kristensen L, Keiserman M, Papp K, McCasland L, White D, Carter K, et al.
Rheumatol Ther
. 2024 Mar;
11(3):617-632.
PMID: 38498141
Introduction: Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well as safety. We present 100-week efficacy and safety results of risankizumab in...
2.
Mease P, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M, et al.
Clin Exp Rheumatol
. 2023 Jul;
41(11):2286-2297.
PMID: 37404160
Objectives: To assess the long-term safety and efficacy of upadacitinib in patients with psoriatic arthritis (PsA) and an inadequate response (IR) to biologic disease-modifying anti-rheumatic drugs (bDMARDs) who completed up...
3.
Kristensen L, Keiserman M, Papp K, McCasland L, White D, Lu W, et al.
Rheumatology (Oxford)
. 2022 Oct;
62(6):2113-2121.
PMID: 36282530
Objective: PsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options with long-term efficacy and safety. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 ...
4.
Kristensen L, Keiserman M, Papp K, McCasland L, White D, Lu W, et al.
Ann Rheum Dis
. 2021 Dec;
81(2):225-231.
PMID: 34911706
Objective: To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying...
5.
Zeng X, Zhao D, Radominski S, Keiserman M, Lee C, Meerwein S, et al.
Int J Rheum Dis
. 2021 Nov;
24(12):1530-1539.
PMID: 34779576
Aim: This study assessed the efficacy and safety of upadacitinib (UPA), in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), in Chinese, Brazilian, and South Korean patients with active rheumatoid...
6.
Mease P, Lertratanakul A, Anderson J, Papp K, Van den Bosch F, Tsuji S, et al.
Ann Rheum Dis
. 2020 Dec;
80(3):312-320.
PMID: 33272960
Background: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to...
7.
Genovese M, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, et al.
J Rheumatol
. 2018 Apr;
45(8):1085-1092.
PMID: 29657147
Objective: To assess 5-year safety, tolerability, and efficacy of subcutaneous (SC) abatacept (ABA) in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA). Methods: The Abatacept Comparison of sub[QU]cutaneous versus intravenous in...
8.
Clowse M, Wallace D, Furie R, Petri M, Pike M, Leszczynski P, et al.
Arthritis Rheumatol
. 2016 Sep;
69(2):362-375.
PMID: 27598855
Objective: Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. The aim of this study was to report the...
9.
Ribeiro S, Albuquerque E, Bortoluzzo A, Goncalves C, da Silva J, Ximenes A, et al.
Rev Bras Reumatol Engl Ed
. 2016 Jun;
56(1):22-7.
PMID: 27267330
Objective: To analyze quality of life and demographic and clinical variables associated to its impairment in a large Brazilian cohort of patients with spondyloarthritis (SpA). Methods: A common protocol of...
10.
da Costa I, Bortoluzzo A, Goncalves C, da Silva J, Ximenes A, Bertolo M, et al.
Rev Bras Reumatol
. 2014 Dec;
55(1):48-54.
PMID: 25542672
Objective: To analyze the results of the application of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in a large series of Brazilian patients with the diagnosis of SpA and...